Ludi Fan, n/a

Eli Lilly and Company
Indianapolis, United States

Disclosure information not submitted.

Presentation(s):

• SAT-722 - Tirzepatide 10 and 15 mg (SURMOUNT-1) vs Semaglutide 7.2 mg (STEP UP) in Adults With Obesity Without Type 2 Diabetes: An Indirect Treatment Comparison

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT